Dr. Wei Wu HePanacea VentureForesite CapitalVenrock Healthcare Capital Partners
Description
CASI Pharmaceuticals, Inc. announced a private investment in public equity financing (PIPE Transaction) that is expected to result in aggregate gross proceeds of approximately $15.0 million. The financing is being led by Venrock Healthcare Capital Partners and Foresite Capital, with participation by Panacea Venture and Dr. Wei-Wu He.
Company Information
Company
CASI Pharmaceuticals
Location
Medical Center Drive
Rockville, Maryland, United States
About
CASI Pharmaceuticals, Inc. is a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is focused on acquiring, developing, and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. The Company intends to execute its plan to become a leader by launching medicines in the Greater China market, leveraging the Company's China-based regulatory and commercial competencies and its global drug development expertise. The Company's operations in China are conducted through its wholly-owned subsidiary, CASI Pharmaceuticals (China) Co., Ltd., located in Beijing, China. The Company has built a commercial team of more than 100 hematology and oncology sales and marketing specialists based in China.
Fundz sees it the moment CASI Pharmaceuticals raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
RockvilleManufacturingBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharma